Stc-15

Sarcoma

STORM Therapeutics LTDPhase 1/2Active

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 73/ 100

Competitive context

109 Active assets in the Sarcoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE National Cancer Institute (NCI)	Phase 2	BB
Ifosfamide City of Hope Medical Center	Phase 3	BB
Cyclophosphamide Essen Biotech	Phase 2	BB
CIS-DIAMMINEDICHLOROPLATINUM II Roswell Park Cancer Institute	Phase 2	BB
Inno-206 City of Hope Medical Center	Phase 3	BB

View all 50 →

Same molecule, other indications

Stc-15 is also rated in:

leiomyosarcomaDormant

CC

Indicative ·

47 / 100

dedifferentiated liposarcomaDormant

CC

Indicative ·

47 / 100

neoplasmDormant

CC

Indicative ·

40 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.